Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Nazan CobanogluUğur ÖzçelikErkan CakirTugba Sismanlar EyubogluSevgi PekcanGüzin CinelEbru YalçınNural KiperNagehan EmiralioğluVelat ŞenHadice Selimoğlu ŞenÖmür ErcanHaluk ÇokuğraşAyse Ayzit KilincLina Muhammed Al ShadfanHakan YazanDerya Ufuk AltıntaşDilek KaragözEsen DemirGökçen Kartal ÖztürkAyşen BingölAbdurrahman Erdem BaşaranNihat SapanŞükrü ÇekiçEbru ÇelebioğluAyşe Tana AslanTuğba Ramaslı GürsoyGökçen TuğcuAli OzdemirKoray HarmancıGonca Kılıç YıldırımMehmet KöseMelih HangülZeynep TamayAyşe SüleymanHasan YükselOzge YılmazGizem ÖzcanErdem TopalDemet CanPervin Korkmaz EkrenGönül ÇaltepeMehmet KılıçŞebnem ÖzdoğanDeniz Dogru ErsozPublished in: Pediatric pulmonology (2020)
The present study shows that approximately one-fourth of the registered CF patients in Turkey are eligible for modulator drugs. As, frequent mutations that CF patients have in Turkey are different from North American and European CF patients, developing modulator drugs effective for those mutations is necessary. Furthermore, as modulator drugs are very expensive currently, financial support of the government in developing countries like Turkey is noteworthy.